Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Evaxion Biotech ( (EVAX) ).
On May 22, 2025, Evaxion A/S announced the dosing of the first patient in the extension of its phase 2 trial for the AI-designed personalized cancer vaccine, EVX-01. This extension aims to explore the vaccine’s potential as a monotherapy for advanced melanoma, following its initial combination with standard anti-PD-1 therapy. The trial extension will provide insights into the long-term clinical and immune benefits of EVX-01, with minimal additional costs due to existing clinical site operations. This development could position EVX-01 as a standalone treatment option, offering a meaningful alternative for patients with advanced melanoma.
The most recent analyst rating on (EVAX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
Evaxion Biotech’s overall stock score reflects significant financial challenges despite strong revenue growth and positive strategic partnerships. While there is optimism from recent clinical successes and strategic partnerships, the persistent net losses, reliance on debt, and negative cash flow are critical concerns impacting the stock’s attractiveness. Technical indicators also suggest some caution.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a pioneering TechBio company based in Denmark, specializing in developing AI-Immunology™ powered vaccines. The company focuses on creating novel immunotherapies for cancer, bacterial diseases, and viral infections using its proprietary AI platform, AI-Immunology™. Evaxion has developed a clinical-stage oncology pipeline of personalized vaccines and a preclinical infectious disease pipeline targeting high unmet medical needs.
Average Trading Volume: 74,646
Technical Sentiment Signal: Sell
Current Market Cap: $2.45M
For an in-depth examination of EVAX stock, go to TipRanks’ Stock Analysis page.